How PD-L1 Biomarker Test Results Impact Clinical Management of Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Listen as Dr. Michaelis discusses the unique aspects of the system burdens of polycythemia vera, the difficult approach to treat and the options to treat.Supported through funding from Incyte
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler Rush of University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain which targetable mutation should be screened for various solid tumors.